Oral drugs may protect cancer patients from blood clots
London, May 13: Taking oral drugs daily can be an effective treatment for nearly 10 million cancer patients worldwide suffering from a deadly blood clot condition, results from a clinical trial have showed.
People with cancer have an increased risk of developing blood clots, with roughly one in five experiencing venous thromboembolism (VTE) -- either a blood clot in a deep vein or a condition in which one or more arteries in the lungs become blocked by a blood clot.
The results from the clinical trial called "select-d" suggested that prescribing the oral drug rivaroxaban significantly reduced VTE recurrence among patients with cancer.
"Clinicians were already adopting the oral drug into practice for non-cancer patients and now they have data from this study to indicate that this form of treatment is an alternative option for many cancer patients who have a clot," said lead author Annie Young, Professor at University of Warwick in the Britain.
Although there are many causes and risk factors for VTE, cancer patients are particularly at risk due to a combination of factors such as immobility, pancreatic and gastric tumours as well as chemotherapy, the researcher said.
For the "select-d" trial, researchers enrolled 406 patients who had cancer and VTE; most (69 per cent) were receiving cancer treatment (typically chemotherapy) at the time of their VTE.
Half were randomly assigned to receive low-molecular-weight heparin (dalteparin) and half were given the oral drug rivaroxaban. After six months of treatment, the VTE recurrence rate was four per cent among those taking the tablet and 11 per cent in those receiving dalteparin.
The results for secondary outcomes were mixed, the researcher said.
In patients receiving rivaroxaban, there were around the same percentage of major bleeding events (6 per cent) as those receiving dalteparin (4 per cent) but a marked and significant increase in clinically relevant non-major bleeds (13 per cent) with rivaroxaban compared to those having low molecular weight heparin (4 per cent).
The reason for increased bleeding is not known. It may be because rivaroxaban is more 'potent', the paper published in the Journal of Clinical Oncology said.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Regulator DGCA eases flight duty norms for pilots amid IndiGo crisis
Mumbai (PTI): Aviation watchdog DGCA on Friday eased the flight duty norms by allowing substitution of leaves with a weekly rest period amid massive operational disruptions at IndiGo, according to sources.
As per the revised Flight Duty Time Limitations (FDTL) norms, "no leave shall be substituted for weekly rest", which means that weekly rest period and leaves are to be treated separately. The clause was part of efforts to address fatigue issues among the pilots.
Citing IndiGo flight disruptions, sources told PTI that the Directorate General of Civil Aviation (DGCA) has decided to withdraw the provision 'no leave shall be substituted for weekly rest' from the FDTL norms.
ALSO READ: 49 Indigo flights likely to be cancelled from Hyderabad
"In view of the ongoing operational disruptions and representations received from various airlines regarding the need to ensure continuity and stability of operations, it has been considered necessary to review the said provision," DGCA said in a communication dated December 5.
The gaps in planning ahead of the implementation of the revised FDTL, the second phase of which came into force from November 1, have resulted in crew shortage at IndiGo and is one of the key reasons for the current disruptions.
#BREAKING: #DGCA relaxes a clause which debarred airlines to club leaves with weekly rest to mitigate #IndiGo crisis
— Economic Times (@EconomicTimes) December 5, 2025
🔴 Catch the day's latest news here ➠ https://t.co/8eVBGnsJUA 🗞️ pic.twitter.com/KUWc8R2Kso
